Sample size calculation for the one-sample log-rank test-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Sample size calculation for the one-sample log-rank test

Published:2014-10-22 Issue:1 Volume:14 Page:26-33
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceut. Statist.

Author:

Wu Jianrong¹

Affiliation:

1. Department of Biostatistics; St. Jude Children's Research Hospital; Memphis TN 38105 USA

Funder

National Health Insurance Service

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Reference12 articles.

1. Comparing survival of a sample to that of a standard population;Finkelstein;Journal of the National Cancer Institute,2003

2. Analysis of survival data under the proportional hazards model;Breslow;International Statistical Review,1975

3. Testing survival under right censoring and left truncation;Hyde;Biometrika,1977

4. Statistical Models Based on Counting Processes

5. Comparing observed life table data with a known survival curve in the presence of random censorship;Gill;Biometrics,1979

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sample size considerations for single-arm clinical trials with time-to-event endpoint using the gamma distribution;Contemporary Clinical Trials Communications;2024-10

2. Group sequential design for time-to-event outcome with non-proportional hazards using the concept of relative time utilizing two different Weibull distributions;Contemporary Clinical Trials Communications;2024-08

3. A novel Phase II single-arm hybrid design to minimize trial duration and enhance subsequent Phase III trial success rate;Journal of Applied Statistics;2024-07-23

4. Intensity-Modulated Reirradiation Therapy With Nivolumab in Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma;JAMA Oncology;2024-07-01

5. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol;BMC Cancer;2024-05-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3